We have previously demonstrated specific binding sites for adrenomedullin, a novel member of the calcitonin family of peptides, in rat muscles. It is unclear whether these receptors are vascular or muscular. Receptors for the structurally similar calcitonin gene-related peptide (CGRP) are present on myocytes and might be involved in the regulation of myocyte glucose metabolism and control by motor neurons. We investigated whether adrenomedullin binding sites were present on L6 myocytes. 
INTRODUCTION
Adrenomedullin was isolated as a 52-amino-acid peptide from human phaeochromocytomas in 1993 by monitoring its ability to increase platelet cAMP [1] . The rat adrenomedullin cDNA encodes a 50-amino-acid peptide with two deletions and six substitutions compared with the human peptide [2] . Both peptides have an N-terminal ring (formed by an intramolecular disulphide bridge) and a C-terminal amidated residue, relating them structurally to the calcitonin family of peptides, calcitonin, calcitonin gene-related peptide (CGRP) and islet amyloid polypeptide (IAPP) [3] . CGRP and IAPP have multiple well-established effects on muscle glucose metabolism but the receptors involved are yet to be defined [4] .
Adrenomedullin is found in low levels in the circulation but the peptide and its mRNA are abundant in adrenal medulla, heart, lung and kidney in both rat and human [1, 2, 5] . Powerful vasodilator effects of adrenomedullin have been demonstrated in the pulmonary [6] , renal [7, 8] , mesenteric [9] and hindquarters [10] vascular beds. Both vascular endothelial and vascular smooth muscle (VSMC) cells release adrenomedullin [11, 12] , with endothelial cells showing mRNA levels 20 times greater than any tissue, possibly indicating a paracrine mechanism for the vasodilation.
The exact mechanism of adrenomedullin-induced vasodilation is controversial. However, increases in cAMP have been demon- . Stimulation with 10 nM adrenomedullin or CGRP caused an increase in the percentage of total activated cellular cAMPdependent protein kinase from 38 % in resting cells to 100 % and 98 % respectively. Therefore in L6 cells adrenomedullin can bind to CGRP receptors, activating adenylate cyclase and cAMPdependent protein kinase. strated in rat VSMC [13] and bovine aortic endothelial cells [14] . Adrenomedullin binds to vascular CGRP receptors with high affinity [3, 15] , which can mediate vasodilation via increased cAMP (reviewed in [16] ). Indeed, early reports suggested that adrenomedullin-mediated vasodilation and increased cAMP could be blocked by the specific CGRP receptor antagonist fragment, CGRP [9, 15] . Recently, specific adrenomedullin binding sites that do not bind CGRP or CGRP have been demonstrated in rat tissues [17] , endothelial cells [14] and rat VSMC [13] . We have demonstrated considerable specific adrenomedullin binding in muscles, i.e. heart, soleus, gastrocnemius and diaphragm. These binding sites might be vascular or present on the myocytes themselves. CGRP receptors have already been demonstrated on muscle cells [18] and muscle cell lines (L6 myocytes) [19, 20] . These receptors might be involved in communication between motor neurons and skeletal muscle [21] and in the control of muscle glucose metabolism. CGRP inhibits insulin-stimulated soleus muscle glycogen synthesis [22] and insulin-stimulated glucose uptake in L6 cells [20] . It is not yet known whether adrenomedullin can interact at myocyte CGRP receptors.
To determine whether specific adrenomedullin binding sites are present on myocytes we examined the binding of ["#&I]adrenomedullin in the rat skeletal muscle cell line, L6G8C5 (L6 cells). After demonstration of specific adrenomedullin binding and confirmation of the expression of CGRP receptors, we examined whether the peptides mediated an increase in adenylate cyclase activity and whether this effect was mediated by CGRP receptors by using the CGRP receptor antagonist CGRP .
MATERIALS AND METHODS

Materials
L6G8C5 (L6) cells were obtained from the European Collection of Animal Cell Cultures (Porton Down, Salisbury, Wilts., U.K.). All media for cell culture were supplied by Gibco BRL (Paisley, Renfrewshire, Scotland, U.K.). Rat α-CGRP was from ASG University (Szedgel, Hungary) ; rat adrenomedullin from Peptide Institute (Osaka, Japan) ; CGRP 
Cell culture and membrane preparation
Cells were grown in high-glucose Dulbecco's modified Eagle's medium with 10 % (v\v) fetal bovine serum, 100 µg\ml penicillin and 100 µg\ml streptomycin. Confluent cells were cultured for a further 7 days (to allow myotube formation) with medium changes every 3 or 4 days before membrane preparation. Cells were washed with ice-cold PBS and scraped into 50 mM Hepes, pH 7.6, containing 0.25 M sucrose, 15 µg\ml aprotinin, 0.5 µg\ml pepstatin, 0.25 µg\ml leupeptin, 0.25 µg\ml antipain, 0.1 mg\ml benzamidine and 0.1 mg\ml bacitracin. Cells were homogenized and centrifuged at 1000 g for 15 min at 4 mC. The supernatants were centrifuged at 100 000 g for 1 h at 4 mC. The final pellets were resuspended in sucrose-free homogenization buffer and the protein concentration was measured [23] .
Receptor binding assays and chemical cross-linking of receptor-ligand complexes
Rat adrenomedullin was iodinated by the Iodogen method as previously described [17, 24] . Fractions showing binding were sampled, freeze-dried and stored at k80 mC. The specific radioactivity of the label was 10 Bq\fmol. Iodination of rat [tyr!]α-CGRP was also as previously described [25] . The specific radioactivity of the CGRP label was 36 Bq\fmol. For the adrenomedullin binding assay, membranes (100 µg of protein) were incubated for 30 min at 4 mC in binding buffer (20 mM Hepes, pH 7.4, 5 mM MgCl # , 10 mM NaCl, 4 mM KCl, 1 mM EDTA, 1 µM phosphoramidon, 0.25 mg\ml bacitracin and 0.3 % BSA) containing 500 Bq (100 pM) of "#&I-rat adrenomedullin as previously described [17] . In equilibrium competition experiments the concentration of unlabelled peptides was varied from 0 to 1.0 µM. Binding data were analysed by nonlinear regression with ' Receptor-Fit ' (Lundon Software, Cleveland, Ohio, U.S.A.) to calculate the IC &! and concentration of binding sites (B max ). ["#&I]CGRP binding (1000 Bq, 27.8 pM) was performed for 45 min at 22 mC as previously described [25] . Chemical crosslinking with BSOCOES followed by SDS\PAGE was performed as previously described [17, 26, 27] . Membranes were incubated with 12 000 Bq (1.9 nM) of "#&I-rat adrenomedullin or 10 000 Bq (278 pM) of ["#&I]CGRP [28] . Autoradiographs were exposed to Kodak X-Omat film (IBI Ltd, Cambridge, Cambs., U.K.) at k80 mC for 1-10 days before development.
Adenylate cyclase assay
Adenylate cyclase activity in L6 membranes (10 µg of protein) was assayed with the method of Salomon [29] as previously described [30] . Briefly, 10 µg of protein was added to a final volume of 100 µl of assay buffer containing 100 µM GTP, 100 µM ATP, 1 mM cAMP, 20 µM creatine phosphate, 25 mM Tris HCl, pH 7.4, 2 mM MgCl # , 1 mM EDTA, 2 mM 3-isobutyl-1-methyl xanthine (IBMX), 200 µg\ml creatine kinase, 238 Bq of [$H]cAMP and 56 000 Bq of [α-$#P] ATP. The reaction mixture was incubated for 10 min at 30 mC and stopped by the addition of 10 µl of 62.5 % trichloroacetic acid. cAMP was separated by sequential elution through Dowex 50W-X4 (200-400 mesh), H + form (Bio-Rad, Hemel Hempstead, Herts., U.K.) and alumina (Sigma) columns. Isoprenaline (10 µM) was used as a positive control for these membranes.
cAMP-dependent protein kinase (PKA) assay
Cells were exposed to control medium, CGRP (1-100 nM) or adrenomedullin (1-100 nM) in the presence of the phosphodiesterase inhibitor IBMX (50 µM). After treatment, cells were washed with PBS, scraped into 1.5 ml of extraction buffer (10 mM NaH # PO % , 10 mM EDTA, 0.5 mM IBMX, 100 mM NaCl, pH 6.8) and homogenized [31] . PKA activity was assayed by measuring [$#P]ATP incorporation into Kemptide (Leu-ArgArg-Ala-Ser-Leu-Gly). Extract (10 µl) was added to triplicate tubes containing 50 mM Tris, pH 7.5, alone or plus : 5 µM PKA inhibitor (PKI) (6-22) amide [32] ; 10 µM cAMP ; 5 µM PKI (6-22) amide and 10 µM cAMP. The reactions were started by adding 50 µM Kemptide, 100 µM ATP and 7400 Bq of [γ-$#P] ATP to tubes and incubating for 5 min at 30 mC. The reaction was stopped by adding 10 µl of 1 M HCl followed by spotting (20 µl) on to phosphocellulose discs (Gibco BRL). PKA activation was calculated as percentage maximum specific radioactivity. The radioactive counts in tubes containing PKI were subtracted from the corresponding tubes without PKI to give the total and activated PKA.
RESULTS AND DISCUSSION
Effects of adrenomedullin and CGRP on binding of [
I]adrenomedullin and [
I]CGRP in L6 cell membranes
We have previously demonstrated binding sites for adrenomedullin in several muscles including heart, gastrocnemius, soleus and diaphragm [17] , but it was not clear whether these sites were on vascular or muscle cells. Therefore we examined ["#&I]adrenomedullin binding in the rat skeletal muscle cell line L6, which has already been shown to exhibit CGRP binding sites [20] . n l 9) ]. Therefore, to confirm that the CGRP and adrenomedullin binding sites were distinct from each other, competition curves were constructed for each of the "#&I-labelled peptides by using CGRP, CGRP(8-37) and adrenomedullin. ["#&I]Adrenomedullin binding (n l 3) was weakly inhibited by CGRP(8-37) (IC &! 601p298 nM) and CGRP (IC &! 10 µM). Adrenomedullin binding was determined at 4 mC, which is the optimal binding temperature [17] . However, the adenylate cyclase experiments 
Chemical cross-linking of rat [ 125 I]adrenomedullin and CGRP to L6 membranes
Cross-linking of the binding-site-ligand complexes in L6 membranes showed that, in this cell line, specific CGRP and adrenomedullin binding sites have molecular masses of 77-96 and 73-89 kDa respectively (n l 3) (Figure 2) . After subtracting the molecular mass of the peptides this gives molecular masses of 82p5 and 76p4 kDa for the CGRP and adrenomedullin binding sites respectively. Incubation with excess unlabelled adrenomedullin, but not CGRP, resulted in the loss of the band corresponding to ["#&I]adrenomedullin binding. Incubation with excess CGRP or adrenomedullin removed the ["#&I]CGRP band. This confirms that adrenomedullin binds to both adrenomedullin and CGRP binding sites. The calculated molecular mass for the adrenomedullin binding site in L6 cells is considerably different from that calculated for heart and soleus (94p3 kDa) or lung and diaphragm (83p1.4 kDa). These differences in molecular mass might be due to different glycosylations, as seen with the corticotrophin-releasing-hormone receptor [33] , or it is possible that there is more than one subtype of adrenomedullin binding site. Alternatively the differences might be due to comparisons between different experiments.
Adenylate cyclase activation by adrenomedullin and CGRP
It has been previously shown that CGRP is capable of elevating intracellular levels of cAMP in L6 cells [19, 20] ; therefore we examined the ability of adrenomedullin and CGRP to activate adenylate cyclase in L6 membranes. CGRP gave a dose-dependent increase in membrane adenylate cyclase activity over the concentrations 0.1-1000 nM, reaching a plateau between 100 and 1000 nM (Table 1) . Adrenomedullin produced a similar pattern with approximate EC &! values between 1 and 10 nM for both peptides. The CGRP receptor antagonist CGRP(8-37) had no effect by itself at concentrations up to 2 µM. Membranes were also treated with either 10 nM CGRP or 25 nM adrenomedullin and increasing concentrations of CGRP . CGRP(8-37) gave a dose-dependent inhibition of adenylate cyclase activation when stimulated with CGRP or adrenomedullin ( Table 1) . Concentrations of CGRP(8-37) exceeding 25 nM were sufficient to inhibit CGRP-or adrenomedullin-stimulated adenylate cyclase activity completely. At this low concentration of CGRP there would be no expected interaction with adrenomedullin binding sites, strongly suggesting that adrenomedullin is acting via the CGRP binding site.
An earlier study claimed that adrenomedullin exerts its physiological effects in cultured rat VSMCs via specific adrenomedullin binding sites coupled with increased intracellular cAMP [34] . However, in that study CGRP did inhibit the increase in cAMP mediated by adrenomedullin, albeit at high concentrations (100 nM or more). This problem was not discussed in the above 
on adenylate cyclase activity in L6 membranes
Activation of adenylate cyclase in L6 cell membranes was assayed in the presence of 2 mM IBMX as described in the Materials and methods section. In experiment 1, membranes were stimulated with 10 µM isoprenaline or increasing concentrations of CGRP, adrenomedullin or CGRP . In experiment 2, membranes were stimulated with submaximal concentrations of CGRP (10 nM) or adrenomedullin (25 nM) in the presence of increasing concentrations of the CGRP receptor antagonist CGRP . Activities are expressed as meanspS.E.M. (n l 6) and are percentages of the control activity. paper and the lack of binding data for CGRP in these cells makes the experiment difficult to interpret. Adrenomedullin is reported to increase cytoplasmic Ca# + and inositol 1,4,5-trisphosphate concentrations by a cholera-toxin-sensitive G-protein in bovine aortic endothelial cells [14] and to decrease the cytoplasmic Ca# + concentration via a G-protein-linked receptor in pig coronary arteries [35] . In the study on endothelial cells, specific adrenomedullin binding sites were demonstrated but the second-messenger effects were not differentiated from those mediated via CGRP receptors known to be present on endothelial cells. Hence it is not clear from these experiments what the true signal transduction mechanisms of the specific adrenomedullin binding site are. In L6 cells adrenomedullin is certainly able to activate adenylate cyclase, but this activation can be inhibited by CGRP(8-37) with a low IC &! , which in combination with the binding data indicates that this effect is mediated by CGRP receptors. Clearly what is required is an examination of signal transduction by adrenomedullin binding sites without the complicating influences of CGRP receptors. We have shown in Swiss 3T3 cells, which express adrenomedullin but not CGRP binding sites, that adrenomedullin potently increases intracellular cAMP [36] . The definitive answer might now have been provided by Kapas et al. [37] , who reported the cloning and expression of a cDNA coding for a rat adrenomedullin receptor. Expression of the cDNA in COS-7 cells showed a pharmacology similar to our binding data in tissues [17] , and stimulation of transfected cells with adrenomedullin increased cAMP production. The specific adrenomedullin binding site in L6 cells does not seem to be involved in the increase in cAMP and might be coupled to different signalling systems in L6 cells from those in COS-7 cells, be present as an uncoupled form or even be a different subtype of adrenomedullin binding site from that cloned by Kapas et al. [37] .
PKA activation by CGRP and adrenomedullin
Elevation of intracellular cAMP is associated with increased phosphorylation of intracellular proteins by PKA [38] . Extracts of control cells that were assayed for PKA activity incorporated 6.8p0.1 nmol of $#P\min per mg of protein into the substrate, Kemptide, 15 % of which was accounted for by non-PKA kinase activity, i.e. it was not inhibited by the PKI fragment. When maximally activated by cAMP, incorporation rose to 26.2p4.1 nmol of $#P\min per mg of protein, 4 % by kinases other than PKA (n l 3). Stimulation of intact L6 cells with CGRP or adrenomedullin caused a dose-dependent increase in PKA activity, which was significant at 5 nM for both peptides (Figure 3 ). Approximate EC &! values for both peptides were between 1 and 5 nM, with 100 % activation achieved at 10 nM. These results are qualitatively similar to the adenylate cyclase results in terms of EC &! but with the maximum activation of PKA occurring at a lower concentration than that of adenylate cyclase. This could be explained by amplification, i.e. one molecule of agonist binds to one receptor, activating adenylate cyclase, producing many cAMP molecules and activating many PKA holoenzymes. Compared with the levels of PKA activation described by Murray et al. [31] for different tissue extracts, the control level of PKA activity in L6 cells is three times greater.
